Paclitaxel-coated versus uncoated balloon angioplasty for femoropopliteal artery in-stent restenosis

作者
Ridong Wu,Zilun Li,Mian Wang,Guangqi Chang,Chen Yao,Shenming Wang
出处
期刊:International Journal of Surgery [Wolters Kluwer]
卷期号:42: 72-82 被引量:17
标识
DOI:10.1016/j.ijsu.2017.04.057
摘要

BACKGROUND: Several prospective controlled trials have assessed the safety and efficacy of drug-coated balloon angioplasty (DCBA) versus standard balloon angioplasty (POBA) for femoropopliteal in-stent restenosis (ISR). We therefore performed a meta-analysis of prospective controlled trials to pool the results of these trials and obtain more reliable conclusions. METHODS AND RESULTS: Prospective controlled trials comparing DCBA versus POBA were searched through PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, ISI Web of Knowledge, and relevant websites without language or publication date restrictions. The keywords were "drug-eluting balloon," "angioplasty," "femoropopliteal," and "in-stent restenosis." We selected recurrent ISR, freedom from clinically driven target lesion revascularization (TLR), clinical improvement, ankle-brachial index (ABI), and major adverse events (MAEs) as the outcomes of this meta-analysis. Based on the inclusion criteria, we identified 3 prospective clinical trials. The one-year outcomes of DCBA and POBA were as follows: recurrent ISR (34.8% versus 73.1%, respectively; OR, 0.18; 95% CI, 0.10-0.32, Z = 5.56, P < 0.00001), freedom from clinically driven TLR (82.2% versus 54.1%, respectively; OR, 4.20; 95% CI, 2.05-8.61, Z = 3.92, P < 0.0001), clinical improvement (76.2% versus 55.7%, respectively; OR, 2.58; 95% CI, 1.41-4.72, Z = 3.07, P = 0.002), ABI (MD, -0.04; 95% CI, -0.13-0.04, Z = 1.01, P = 0.31), and MAEs (11.0% versus 18.3%, respectively; OR, 0.54; 95% CI, 0.25-1.15, Z = 1.60, P = 0.002). CONCLUSIONS: For femoropopliteal ISR, DCBA is associated with superior efficacy outcomes compared with POBA, with the same safety outcome after a one-year follow-up. In the future, multicenter and large-scale prospective controlled trials comparing DCBA with other endovascular strategies are required to further assess the efficacy and safety profiles of DCBA in the treatment of femoropopliteal ISR.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Code_king发布了新的文献求助10
1秒前
恩雁完成签到,获得积分10
1秒前
Hou发布了新的文献求助10
1秒前
小赵完成签到,获得积分10
1秒前
阿丽完成签到,获得积分20
1秒前
1秒前
徐七鹏发布了新的文献求助10
1秒前
DW的应助被香蕉三娘采纳,获得10
1秒前
1秒前
DW的应助被jjjj采纳,获得10
2秒前
xinda_li完成签到 ,获得积分10
2秒前
2秒前
Foremelon发布了新的文献求助10
2秒前
2秒前
2秒前
3秒前
3秒前
3秒前
Owen的应助被黑皮鞋采纳,获得10
3秒前
心理学小学生完成签到,获得积分10
3秒前
Code_king发布了新的文献求助10
3秒前
3秒前
Code_king发布了新的文献求助10
3秒前
3秒前
黃偉倫发布了新的文献求助10
3秒前
共享精神的应助被云墨采纳,获得10
4秒前
高挑的鱼完成签到 ,获得积分10
4秒前
4秒前
在水一方的应助被11采纳,获得30
4秒前
molihuakai的应助被jerrychen采纳,获得10
4秒前
Jasper的应助被xiaomings007采纳,获得10
4秒前
5秒前
NexusExplorer的应助被煎饼煎饼采纳,获得10
5秒前
下一秒的王的应助被可靠吐司采纳,获得10
5秒前
curry完成签到,获得积分10
6秒前
xliang完成签到,获得积分10
6秒前
51515发布了新的文献求助10
6秒前
6秒前
彭于晏的应助被大刘采纳,获得10
6秒前
英姑的应助被yimeng采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176102
求助须知:如何正确求助?哪些是违规求助? 9567588
关于积分的说明 21793477
捐赠科研通 7770603
什么是DOI,文献DOI怎么找? 3431969
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477522